THE MADISON GROUP

Lobbying for NOVO NORDISK INC. · Pharmaceutical Company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · New Jersey · House · Senate · $90,000.00 income · posted Apr 21, 2025

Lobbying activity 2

Health Issues

Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications, and (4) issues related to compounding and counterfeit drugs.

Medicare/Medicaid

Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.